This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Mar;129(3):384.

doi: 10.1067/msy.2001.113379.

Mutations of the CYP2C9 gene and the response to warfarin

U Yasar, M Oscarson, E Eliasson, F Sjöqvist

PMID: 11231472
DOI: 10.1067/msy.2001.113379

Comment

Mutations of the CYP2C9 gene and the response to warfarin

U Yasar et al. Surgery. 2001 Mar.

. 2001 Mar;129(3):384.

doi: 10.1067/msy.2001.113379.

Authors

U Yasar, M Oscarson, E Eliasson, F Sjöqvist

PMID: 11231472
DOI: 10.1067/msy.2001.113379

No abstract available

PubMed Disclaimer

Comment on

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.
Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Freeman BD, et al. Surgery. 2000 Aug;128(2):281-5. doi: 10.1067/msy.2000.107283. Surgery. 2000. PMID: 10923005

Similar articles

Warfarin dose requirement and CYP2C9 polymorphisms.
Halkin H, Lubetsky A. Halkin H, et al. Lancet. 1999 Jun 5;353(9168):1972-3. doi: 10.1016/S0140-6736(05)77184-1. Lancet. 1999. PMID: 10371596 No abstract available.
CYP2C9 polymorphism and warfarin dose requirements.
Daly AK, Day CP, Aithal GP. Daly AK, et al. Br J Clin Pharmacol. 2002 Apr;53(4):408-9. doi: 10.1046/j.1365-2125.2002.01572_6.x. Br J Clin Pharmacol. 2002. PMID: 11966680 Free PMC article. No abstract available.
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Furuya H, et al. Pharmacogenetics. 1995 Dec;5(6):389-92. doi: 10.1097/00008571-199512000-00008. Pharmacogenetics. 1995. PMID: 8747411 No abstract available.
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
Redman AR. Redman AR. Pharmacotherapy. 2001 Feb;21(2):235-42. doi: 10.1592/phco.21.2.235.34106. Pharmacotherapy. 2001. PMID: 11213860 Review.
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
Miners JO, Birkett DJ. Miners JO, et al. Br J Clin Pharmacol. 1998 Jun;45(6):525-38. doi: 10.1046/j.1365-2125.1998.00721.x. Br J Clin Pharmacol. 1998. PMID: 9663807 Free PMC article. Review.

See all similar articles

Cited by

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
Oner Ozgon G, Langaee TY, Feng H, Buyru N, Ulutin T, Hatemi AC, Siva A, Saip S, Johnson JA. Oner Ozgon G, et al. Eur J Clin Pharmacol. 2008 Sep;64(9):889-94. doi: 10.1007/s00228-008-0507-5. Epub 2008 Jun 10. Eur J Clin Pharmacol. 2008. PMID: 18542936

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information